MUSTANG BIO, INC.
About MUSTANG BIO, INC.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2019
- $0
- Net income
- -$1.9M
- Total assets
- $17.6M
- Market cap
- $5.1M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $5.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 22, 2017
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review MUSTANG BIO, INC..